Med Lett Drugs Ther. 2011 Apr 18;53(1362):30-1.
Eribulin mesylate (Halaven-Eisai) has been approved by the FDA for treatment of patients with metastatic breast cancer who have previously received at least 2 chemotherapy regimens for metastatic cancer. Prior therapy should have included an anthracycline and a taxane in either an adjuvant or metastatic setting. Other drugs used to treat anthracycline- and taxane-refractory metastatic breast cancer include capecitabine (Xeloda), gemcitabine (Gemzar, and others) and vinorelbine (Navelbine, and others).
甲磺酸艾瑞布林（商品名：Halaven - Eisai）已获美国食品药品监督管理局（FDA）批准，用于治疗既往接受过至少2种转移性癌症化疗方案的转移性乳腺癌患者。先前的治疗应在辅助治疗或转移性治疗中包含蒽环类药物和紫杉烷类药物。其他用于治疗对蒽环类药物和紫杉烷类药物耐药的转移性乳腺癌的药物包括卡培他滨（希罗达）、吉西他滨（健择等）和长春瑞滨（诺维本等）。
